ArticleJournal of the American Heart Association2025
Randomized Controlled Preclinical Trial of a Benzodiazepine-Dihydropyridine Hybrid Molecule in Rodent Stroke.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Randomized Controlled Preclinical Trial of a Benzodiazepine-Dihydropyridine Hybrid Molecule in Rodent Stroke.Journal of the American Heart Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 3-ethoxycarbonyl-2-methyl-4-(2-nitrophenyl)-4,11-dihydro-1H-pyrido[2,3-b][1,5]benzodiazepine (JM-20) molecule is a novel multifunctional molecule with potent neuroprotective effects in rat focal cerebral ischemia. To confirm previous results obtained in single laboratories with small sample sizes, and to provide a robust preclinical evidence base for potential clinical development in stroke, we performed a 2-center preclinical trial with sufficiently large group sizes to detect relevant effects, minimizing biases in experimental design as much as possible (randomization, blinding, predefined in- and exclusion criteria) and increasing external and construct validities.
methodsExperimental focal cerebral ischemia was induced by different surgeons in 2 different laboratories on 2 continents, including 2 species (480 mice and 55 rats), different suppliers, mature adult and middle-aged male animals (age range, 2-16 months) as well as comorbid animals (streptozotocin-induced diabetes).
resultsAlthough JM-20 improved functional outcomes after middle cerebral artery occlusion in young adult mice at day 7 and appeared to reduce mortality (not statistically significant), it had no effect on mature adult or comorbid mice. Effect sizes, where statistically significant, were modest, and much lower than those reported in the previous studies. Meta-analysis of all individual mouse data did not reveal statistically significant different functional outcomes or mortalities between vehicle- and JM-20-treated animals, although neuroscores and survival were slightly better in JM-20-treated animals. In the less-severe model of permanent cortical focal cerebral ischemia in rats, JM-20 significantly reduced brain infarction.
conclusionsWe were able to confirm the neuroprotective potential of JM-20. However, effect sizes were substantially lower than previously described in small monocentric trials. Further study is needed to determine whether JM-20 could be effective in less-severe cases of focal cerebral ischemia or when used in combination with thrombolysis. REGISTRATION: URL: Unique identifier: DOI: 10.17590/asr.0000181.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.